Related Experiment Video
Updated: Jul 6, 2026
07:28
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Ciprofloxacin-induced Q-T interval prolongation
John P Knorr1, Mersedeh Moshfeghi, Mary C Sokoloski
1Albert Einstein Medical Center, Philadelphia, PA 19141, USA. knorr.john@gmail.com
Summary
A pediatric patient with Crohn's disease experienced Q-T interval prolongation after starting ciprofloxacin. The condition resolved after discontinuing the antibiotic, highlighting a potential drug-induced cardiac side effect.
Area of Science:
- Pediatric Cardiology
- Pharmacology
- Gastroenterology
Background:
- Crohn's disease is a chronic inflammatory condition.
- Prolonged Q-T interval can lead to serious cardiac arrhythmias.
- Identifying iatrogenic causes of Q-T prolongation is crucial in pediatric care.
Observation:
- A 16-year-old boy with a history of Crohn's disease presented with an acute flare and perirectal abscess.
- Treatment with intravenous ciprofloxacin was initiated.
- Within 48 hours, the patient developed bradycardia and a prolonged Q-T interval (486 msec).
Findings:
- The patient's Q-T interval normalized within seven days of discontinuing ciprofloxacin.
- No further cardiac anomalies were observed.
- This suggests ciprofloxacin as a potential cause of Q-T interval prolongation in this patient.
Implications:
- This case highlights a potential adverse effect of ciprofloxacin in pediatric patients.
- Clinicians should monitor for Q-T interval prolongation in pediatric patients receiving ciprofloxacin, especially those with underlying conditions.
- Further investigation into fluoroquinolone-induced cardiotoxicity in children may be warranted.
Related Concept Videos
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...